Octreotide (SMS 201-995) in the treatment of metastatic glucagonoma: report of one case and review of the literature.

Abstract	We report 1 patient with a necrolytic migratory erythema, a high plasma glucagon concentration and a metastatic pancreatic endocrine tumor who has now been treated effectively for 33 months with the somatostatin analogue octreotide (SMS 201-995) (400 micrograms/day). The results of SMS 201-995 in the treatment of glucagonoma syndrome are reviewed.
Authors	A Rosenbaum, B Flourie, S Chagnon, M Blery, R Modigliani
Journal	Digestion (Digestion) Vol. 42 Issue 2 Pg. 116-20 ( 1989) ISSN: 0012-2823 [Print] Switzerland
PMID	2548911 (Publication Type: Case Reports, Journal Article, Review)
Chemical References	Octreotide
Topics	Adenoma, Islet Cell (drug therapy) Aged Female Glucagonoma (drug therapy, secondary) Humans Octreotide (therapeutic use) Pancreatic Neoplasms (drug therapy) Syndrome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!